

Pharmaids Pharmaceuticals Limited.

4-4-211/212/11-12, Inderbagh, Hyderabad – 500 095.

Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com

CIN No. L52520TG1989PLC009679

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2014
(Amt in lakhs)

PART - I

S. No	Particulars	QUARTER ENDED			YEAR ENDED
		30.06.2014	31.03.2014	30.06.2013	31.03.2014
		Un-audited			Audited
1	Income from Operations				140.52
	(a) Net Sales/Income from operations	45.17	40.44	27.13	0.00
	(b) Other Operating Income	0.00	0.00	0.00	140.52
	Total Income from Operations	45.17	40.44	27.13	
2	Expenses				0.00
	a. Consumption of raw materials	2.91	0.00	1.11	103.94
	b. Purchases of stock-in-trade	21.25	35.32	15.97	(5.52)
	c. Increase/decrease in stock in trade and WIP	(2.09)	(5.43)	3.13	0.00
	d. Power & Fuel	0.00	0.00	0.00	0.00
	e. Sales Tax and other Taxes	0.00	0.00	0.00	9.55
	f. Employees Cost	4.44	1.81	1.86	8.00
	g. Depreciation	1.68	2.00	2.00	76.18
	h. Other expenditure	22.82	45.48	5.58	192.15
	Total	51.01	79.18	29.65	
	(Any item exceeding 10% of the total expenditure to be shown separately)	0.00	0.00	0.00	0.00
3	Profit / (Loss) from Operations before	(5.84)	(38.74)	(2.52)	15.84
4	Other Income	7.58	7.36	4.50	
5	Profit / (Loss) from Ordinary activities before finance costs and exceptional items	1.74	(31.38)	1.98	(35.79)
6	Finance Cost	0.00	0.30	0.17	0.81
7	Profit / (Loss) from Ordinary activities after finance costs but before exceptional items	1.74	(31.68)	1.81	(36.60)
8	Exceptional Items - Expenditure / (Income)	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary Activities before tax	1.74	(31.68)	1.81	(36.60)
10	Tax expense				0.00
	a) Provision for Taxation	0.00	0.00	0.00	(1.17)
	b) Provision for Deferred tax	0.00	0.00	0.00	0.00
	c) MAT Credit	0.00	0.00	0.00	
11	Net Profit (+)/ Loss (-) from ordinary activities after tax	1.74	(31.68)	1.81	(35.43)
12	Extraordinary items (net of tax expense Rs.Nil)	Nil	Nil	Nil	Nil
13	Net Profit (+)/Loss (-) for the period	1.74	(31.68)	1.81	(35.43)
14	Paid-up equity share capital (Face value of the Share is Rs 10/- each)	336.31	336.31	336.31	336.31
15	Reserves excluding Revaluation Reserves as per balance sheet of previous	9.94	9.94	9.94	9.94
16	Earnings Per Share (before extraordinary items - not annualised)				
	a) Basic	0.05	(0.93)	0.05	(1.04)
	b) Diluted	0.05	(0.93)	0.05	(1.04)



17	Earnings Per Share (after extraordinary items - not annualised)				
		0.05	(0.93)	0.05	(1.04)
a)	Basic	0.05	(0.93)	0.05	(1.04)
b)	Diluted				

PART - II

A. Particulars of Shareholding

1	Public shareholding	3166405	3166405	3166405	3166405
	- Number of shares				
	- Percentage of shareholding	92.98%	92.98%	92.98%	92.98%
2	Promoters and Promoter Group				
	Shareholding				
a	Pledged/Encumbered - No. of Shares	NIL	NIL	NIL	NIL
	percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
	percentage of shares (as a % of the total share capital of the Company)	NIL	NIL	NIL	NIL
b	Non - encumbered				
	Number of shares	239095	239095	239095	239095
	percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
	percentage of shares (as a % of the total share capital of the company)	7.02%	7.02%	7.02%	7.02%

B.	Particulars	3 months ended 30/06/2014
	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil

Notes:

- The above results have been reviewed by the Audit Committee and taken on by the Board at its Meeting held on 14th day of August 2014.
- Figures for the previous Year/Quarter/ Half yearly have been rearranged / regrouped wherever necessary.
- The Company's exclusive business is manufacturing and selling of Drugs Formulation and as such this is the only reportable segment as per Accounting Standard - 17 on segment reporting issued by the ICAI
- Provisions for Income Tax and Differed Tax will be made at the end of the Financial Year

For PHARMAIDS PHARMACEUTICALS LIMITED

Chairman & Managing Director

PLACE : HYDERABAD

DATE : 14.08.2014





Date :

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of un-audited standalone financial results of **PHARMAIDS PHARMEUTICALS LIMITED** ("the Company") for the quarter ended 30th June, 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter Group Shareholding' which has been traced from disclosures made by the management and has not been audited by us. The statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an opinion. We have not performed an audit and accordingly we do not express such an opinion.

Management has informed to us being quarterly closing, the company has not accounted for taxes on income as required under AS-22 i.e. Deferred Tax and Income Tax and Provision for Gratuity as per AS-15 Employee Benefits, the same will be considered at the time of year end. Further the depreciation for this quarter is accounted as per Schedule II to the Companies Act, 2013. The impact of the depreciation for this quarter is that the profit is shown more by 0.34 Lakhs. However the difference between the Depreciation as per Schedule XIV of the Companies Act, 1956 and as per Schedule II to the Companies Act, 2013 upto 31-03-2014 is to be adjusted out of retained earnings. As informed by the management, the same will be considered at the year end.

Based on our review conducted as above and subject to the points mentioned above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the Accounting Standards issued under the Companies (Accounting Standards) Rules, 2006 which continue to apply as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting policies and practices generally accepted in India has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchange including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **RAKESH S JAIN & ASSOCIATES**

Chartered Accountants

Firm Reg No. 010129S

(B. RAMESH KUMAR)

Partner

M. No. 200304

Date: 14-8-2014
Place: Hyderabad.

